Abstract
Background The biosimilarity for erythropoietin (EPO) functionality of GBPD002 (test candidate) and Eprex® (comparator) has been evaluated by comparing the pharmacokinetic (PK) and pharmacodynamic (PD) properties following subcutaneous injection.
Methods This was a randomized, double-blinded, two-sequence, crossover clinical trial. Subjects were randomly assigned and received a dose (4,000 IU) of either the test or comparator EPO, and received the alternative formulations after 4-weeks of washout period.
Results The PK parameters, viz., maximum observed concentration (Cmax) and area under the curve extrapolated to infinity (AUC0-inf), were calculated with the serum EPO concentrations from blood samples and were found comparable for both formulations. The geometric mean ratios (at 90% CI) of the Cmax and AUCinf were 0.89 and 1.16, respectively, which were within the regulatory range of 0.80 – 1.25. The time-matched serum EPO concentrations and PD markers (reticulocyte, hematocrit, hemoglobin, and red blood cell) denoted a counterclockwise hysteresis, suggesting a time delay between the observed concentration and the response. ANOVA-derived P-values (>0.05) for the effectors clearly revealed the similarity between effects on PD markers for the test and comparator drugs. Both formulations were found tolerated well, and anti-drug antibodies were not observed.
Conclusions Thus, the two formulations are projected to be used interchangeably in clinical settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05585658
Funding Statement
Globe Biotech Limited funded this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol for the study has got ethical clearance from the institutional review board (IRB; The Ethics Committee of Farabi General Hospital Ltd.) and was approved by the Directorate General of Drug Administration (DGDA) of Bangladesh
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- CV
- coefficient of variation
- SD
- standard variation
- CI
- confidence interval
- GMR
- geometric mean ratio aGMR: (90% CI) of the test to the comparator epoetin alfa
- b Tmax (h)
- Mean (lowest-highest)
- AUC0–144 h
- area under the curve from time zero to the time of the last observation
- AUC0-inf
- area under the curve extrapolated to infinity
- Cmax
- maximum observed serum EPO concentration
- CL/F
- total clearance
- MRTlast
- mean residence time
- t1/2
- terminal half-life
- aTmax
- time of Cmax
- SD
- standard deviation, aMean difference (90% CI) between the test and the comparator epoetin alfa
- ANOVA
- analysis of variance
- ΔAUEC
- area under the baseline-adjusted effect curve
- ΔEmax
- maximum effect change
- bTmax
- time of Emax
